Pfiz­er projects mR­NA vac­cine sales will hov­er around $15B by 2030

Pfiz­er’s mR­NA vac­cines have been a high point for the com­pa­ny dur­ing the pan­dem­ic, and even with dwin­dling de­mand and gov­ern­ment re­sources, the phar­ma is pre­dict­ing $10 bil­lion to $15 bil­lion in an­nu­al rev­enue by 2030 for its mR­NA vac­cine port­fo­lio (in­clud­ing Comir­naty, flu, the com­bo of Covid-flu, and shin­gles).

While high­light­ing ma­jor 2022 vac­cine read­outs for its pen­tava­lent meningo­coc­cal vac­cine can­di­date, its RSV vac­cine can­di­date, Pre­vnar 20 (which Pfiz­er is hop­ing to co-ad­min­is­ter with its sea­son­al flu vac­cine), and more Comir­naty da­ta, CFO Dave Den­ton pro­ject­ed a 2023 core rev­enue growth of 7% to 9%, from $43.9 bil­lion in 2022 to $46.6 bil­lion in 2023, with a full pipeline of vac­cines for flu, Covid and flu, and shin­gles.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER